A budget impact analysis of gene therapy for sickle cell disease: an updated analysis-Reference-Cited by-同舟云学术

A budget impact analysis of gene therapy for sickle cell disease: an updated analysis

Published:2024-08-30 Issue:17 Volume:8 Page:4658-4661
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

DeMartino Patrick C.¹,Haag Meredith B.¹,Caughey Aaron B.²,Roth Joshua A.³^ORCID

Affiliation:

1. 1Department of Pediatrics, Oregon Health & Science University, Doernbecher Children’s Hospital, Portland, OR

2. 2Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR

3. 3University of Washington School of Pharmacy, Fred Hutchinson Institute for Cancer Outcomes Research, Seattle, WA

Publisher

American Society of Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/8/17/4658/2241206/blooda_adv-2024-013093-main.pdf

Reference16 articles.

1. Efficacy and safety of a single dose of exagamglogene autotemcel for severe sickle cell disease;Frangoul;Blood,2022

2. Lovo-cel (bb1111) gene therapy for sickle cell disease: updated clinical results and investigations into two cases of anemia from group C of the phase 1/2 HGB-206 study;Walters;Blood,2022

3. Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis;DeBaun;Blood,7 2019

4. Center for International Blood & Marrow Transplant Research . Summary slides & reports. Accessed 2 December 2023. https://cibmtr.org/CIBMTR/Resources/Summary-Slides-Reports.

5. Tufts Medicine: Center for Biomedical System Design . Designing financial solutions to ensure affordable access to cures. 2018. Accessed 2 December 2023. https://newdigs.tuftsmedicalcenter.org/designing-financial-solutions-to-ensure-affordable-access-to-cures/.